Prognostic value of clinical variables in ovarian cancer

Journal of Clinical Epidemiology

Volumn 50, Issue 5, 1997, Pages 501-505

  DiSilvestro, Paul ^a   Peipert, Jeffrey F ^a   Hogan, Joseph W ^b   Granai, Cornelius O ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Epidemiology; Neoplasm staging; Ovarian neoplasms; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CLASSIFICATION; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SYMPTOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0031010218     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00002-4     Document Type: Article

References (18)

1. Charlson ME, Feinstein AR. The auxometric dimension: A new method for using rate of growth in prognostic staging of breast cancer. JAMA 1974; 228: 180-185.
2. Wells CK, Stoller JK, Feinstein AR, Horwitz RI. Co-morbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984; 144: 2004-2009.
3. Peipert JF, Wells CK, Schwartz PE, Feinstein AR. The impact of symptoms and co-morbidity on prognosis in stage IB cervical cancer. Am J Obstet Gynecol 1993; 169: 598-604.
4. Peipert JF, Wells CK, Schwartz PE, Feinstein AR. Prognostic value of clinical variables in invasive cervical cancer. Obstet Gynecol 1994; 84: 746-751.
5. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine 1990; 69: 1-30.
6. Piccirillo JF, Sasaki CT, Wells CK, Feinstein AR. New clinical severity staging system for cancer of the larynx: Five-year survival rates. Ann Otol Rhinol Laryngol 1994; 103: 83-92.
7. Feinstein AR, Schimpff CR, Hull EW. A reappraisal of staging and therapy for patients with cancer of the rectum. I. Development of two systems of staging. Arch Intern Med 1975; 135: 1441-1453.
8. Feinstein AR, Schimpff CR, Hull EW. A reappraisal of staging and therapy for patients with cancer of the rectum. II. Patterns of presentation and outcome. Arch Intern Med 1975; 135: 1454-1462.
9. Clemens JD, Feinstein AR, Holabird N, Cartwright S. A new clinical-anatomic staging system for evaluating prognosis and treatment of prostate cancer. J Chronic Dis 1986; 39: 913-928.
10. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA-A Cancer Journal for Clinicians 1995; 45: 8-30.
11. Feinstein AR, Pritchett JA, Schimpff CR. The epidemiology of cancer therapy: III. The management of imperfect data. Arch Intern Med 1969; 123: 448-461.
12. Feinstein AR, Pritchett JA, Schimpff CR. The epidemiology of cancer therapy: IV. The extraction of data from medical records. Arch Intern Med 1969; 123: 571-590.
13. Kaplan M, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
15. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990; 77: 147-160.
16. Feinstein AR. Symptoms as an index of biologic behavior and prognosis in human cancer. Nature (Lond) 1966; 209: 241-245.
17. Feinstein AR. A new staging system for cancer and a reappraisal of "early" treatment and "cure" by radical surgery. N Engl J Med 1968; 279: 747-753.
18. MacDonald I. Individual basis of biologic variability in cancer. Surg Gynecol Obstet 1958; 106: 227-229.